These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 6105474)

  • 1. Clinical trial of desferrioxamine entrapped in red cell ghosts.
    Green R; Lamon J; Curran D
    Lancet; 1980 Aug; 2(8190):327-30. PubMed ID: 6105474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancement of iron chelation by desferrioxamine entrapped in red blood cell ghosts.
    Green R; Miller J; Crosby W
    Blood; 1981 May; 57(5):866-72. PubMed ID: 7214016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Controlled desferrioxamine treatment of congenital anaemia and transfusion siderosis (author's transl)].
    Arnold H; Wehinger H; Deus B; Löhr GW
    Dtsch Med Wochenschr; 1978 Aug; 103(31):1240-4. PubMed ID: 668572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High dosage desferrioxamine therapy in a female patient with acquired aplastic anaemia and transfusion siderosis.
    Breithaupt H; Heckers H; Pralle H; Guttmann W; Bleyl H; Graef V; Jundt G
    Blut; 1986 Apr; 52(4):211-9. PubMed ID: 3634632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients.
    Olivieri NF; Koren G; Hermann C; Bentur Y; Chung D; Klein J; St Louis P; Freedman MH; McClelland RA; Templeton DM
    Lancet; 1990 Nov; 336(8726):1275-9. PubMed ID: 1978115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Excretion of iron in response to deferoxamine in sickle cell anemia.
    Cohen A; Schwartz E
    J Pediatr; 1978 Apr; 92(4):659-62. PubMed ID: 633013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of ascorbic acid deficiency on desferrioxamine-induced urinary iron excretion.
    Wapnick AA; Lynch SR; Charlton RW; Seftel HC; Bothwell TH
    Br J Haematol; 1969 Dec; 17(6):563-8. PubMed ID: 5357744
    [No Abstract]   [Full Text] [Related]  

  • 8. Subcutaneous infusion and intramuscular injection of desferrioxamine in patients with transfusional iron overload.
    Hussain MA; Green N; Flynn DM; Hussein S; Hoffbrand AV
    Lancet; 1976 Dec; 2(7998):1278-80. PubMed ID: 63749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Iron chelation with oral desferrioxamine.
    Jacobs A; Ting WC
    Lancet; 1980 Oct; 2(8198):794. PubMed ID: 6107464
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of subcutaneous deferoxamine and oral vitamin C on iron excretion in congenital hypoplastic anemia and refractory anemia associated with the 5q-syndrome.
    Ambruso DR; Mahony BS; Githens JH; Rhoades ED
    Am J Pediatr Hematol Oncol; 1982; 4(2):115-23. PubMed ID: 7114394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous and subcutaneous desferrioxamine therapy in children with severe iron overload.
    Janka GE; Möhring P; Helmig M; Haas RJ; Betke K
    Eur J Pediatr; 1981 Nov; 137(3):285-90. PubMed ID: 7318841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of dose, time, and ascorbate on iron excretion after subcutaneous desferrioxamine.
    Hussain MA; Green N; Flynn DM; Hoffbrand AV
    Lancet; 1977 May; 1(8019):977-9. PubMed ID: 67469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Continuous subcutaneous administration of deferoxamine in patients with iron overload.
    Propper RD; Cooper B; Rufo RR; Nienhuis AW; Anderson WF; Bunn HF; Rosenthal A; Nathan DG
    N Engl J Med; 1977 Aug; 297(8):418-23. PubMed ID: 882111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reassessment of the use of desferrioxamine B in iron overload.
    Propper RD; Shurin SB; Nathan DG
    N Engl J Med; 1976 Jun; 294(26):1421-3. PubMed ID: 1272274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Iron absorption in iron-loading anaemias: Effect of subcutaneous desferrioxamine infusions.
    Pippard MJ; Callender ST; Warner GT; Weatherall DJ
    Lancet; 1977 Oct; 2(8041):737-9. PubMed ID: 71542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Desferrioxamine induced urinary iron excretion in thalassemia.
    Dubey AP; Kumar S; Choudhury P; Talukdar B; Puri RK
    Indian Pediatr; 1993 Jun; 30(6):775-8. PubMed ID: 8132258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improvement in iron status and liver function in patients with transfusional iron overload with long-term subcutaneous desferrioxamine.
    Hoffbrand AV; Gorman A; Laulicht M; Garidi M; Economidou J; Georgipoulou P; Hussain MA; Flynn DM
    Lancet; 1979 May; 1(8123):947-9. PubMed ID: 87616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Red cell ghost-entrapped deferoxamine as a model clinical targeted delivery system for iron chelators and other compounds.
    Green R
    Bibl Haematol; 1985; (51):25-35. PubMed ID: 4004761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Long-term study in congenital refractory anemia and secondary siderosis].
    Tuschy U; Schmidt U; Meinhold J; Wutke K
    Z Gesamte Inn Med; 1982 Apr; 37(7):213-7. PubMed ID: 7102009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Transfusion induced hypersiderosis in aplastic anemia--physiopathology and therapeutic aspects].
    Andres J
    Z Gesamte Inn Med; 1983 Feb; 38(3):81-3. PubMed ID: 6845780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.